Acyl‐Coenzyme A Thioesterase 9 Traffics Mitochondrial Short‐Chain Fatty Acids Toward De Novo Lipogenesis and Glucose Production in the Liver
Authors:
- 4 June 2020
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 72 (3) , 857-872
Abstract
Background and Aims: Obesity‐induced pathogenesis of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) is associated with increased de novo lipogenesis (DNL) and hepatic glucose production (HGP) that is due to excess fatty acids. Acyl‐coenzyme A (CoA) thioesterase (Acot) family members control the cellular utilization of fatty acids by hydrolyzing (deactivating) acyl‐CoA into nonesterified fatty acids and CoASH. Approach and Results: Using Caenorhabditis elegans, we identified Acot9 as the strongest regulator of lipid accumulation within the Acot family. Indicative of a maladaptive function, hepatic Acot9 expression was higher in patients with obesity who had NAFLD and NASH compared with healthy controls with obesity. In the setting of excessive nutrition, global ablation of Acot9 protected mice against increases in weight gain, HGP, steatosis, and steatohepatitis. Supportive of a hepatic function, the liver‐specific deletion of Acot9 inhibited HGP and steatosis in mice without affecting diet‐induced weight gain. By contrast, the rescue of Acot9 expression only in the livers of Acot9 knockout mice was sufficient to promote HGP and steatosis. Mechanistically, hepatic Acot9 localized to the inner mitochondrial membrane, where it deactivated short‐chain but not long‐chain fatty acyl‐CoA. This unique localization and activity of Acot9 directed acetyl‐CoA away from protein lysine acetylation and toward the citric acid (TCA) cycle. Acot9‐mediated exacerbation of triglyceride and glucose biosynthesis was attributable at least in part to increased TCA cycle activity, which provided substrates for HGP and DNL. β‐oxidation and ketone body production, which depend on long‐chain fatty acyl‐CoA, were not regulated by Acot9. Conclusions: Taken together, our findings indicate that Acot9 channels hepatic acyl‐CoAs toward increased HGP and DNL under the pathophysiology of obesity. Therefore, Acot9 represents a target for the management of NAFLD.Keywords
Funding Information
- American Liver Foundation (Alexander M. White, III Memorial Postdoctoral Rese)
- Belgian American Educational Foundation (Postdoctoral Fellowship)
- Medical College, Weill Cornell Medicine (Department of Medicine Seed Grant for Innovative R, Department of Medicine Startup funds)
This publication has 37 references indexed in Scilit:
- Targeted deletion of thioesterase superfamily member 1 promotes energy expenditure and protects against obesity and insulin resistanceProceedings of the National Academy of Sciences, 2012
- Excessive Hepatic Mitochondrial TCA Cycle and Gluconeogenesis in Humans with Nonalcoholic Fatty Liver DiseaseCell Metabolism, 2011
- SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylationNature, 2010
- Lipotoxicity in nonalcoholic fatty liver disease: not all lipids are created equalExpert Review of Gastroenterology & Hepatology, 2009
- Monocyte Chemoattractant Protein-1 (MCP-1): An OverviewJournal of Interferon & Cytokine Research, 2009
- C. elegans fat storage and metabolic regulationBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2009
- The evolutionary fate of recently duplicated retrogenes in miceJournal of Evolutionary Biology, 2006
- Design and validation of a histological scoring system for nonalcoholic fatty liver disease†Hepatology, 2005
- CytochromecAssociation with the Inner Mitochondrial Membrane Is Impaired in the CNS of G93A-SOD1 MiceJournal of Neuroscience, 2005
- The liver isoform of carnitine palmitoyltransferase 1 is not targeted to the endoplasmic reticulumBiochemical Journal, 2003